These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 21045757)
41. Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. Scahill L; McCracken JT; King BH; Rockhill C; Shah B; Politte L; Sanders R; Minjarez M; Cowen J; Mullett J; Page C; Ward D; Deng Y; Loo S; Dziura J; McDougle CJ; Am J Psychiatry; 2015 Dec; 172(12):1197-206. PubMed ID: 26315981 [TBL] [Abstract][Full Text] [Related]
42. Weight and Height in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Longitudinal Database Study Assessing the Impact of Guanfacine, Stimulants, and No Pharmacotherapy. Schneider G; Banaschewski T; Feldman BL; Gustafsson PA; Murphy B; Reynolds M; Coghill DR; Spalding WM J Child Adolesc Psychopharmacol; 2019 May; 29(4):285-304. PubMed ID: 30942617 [No Abstract] [Full Text] [Related]
43. Efficacy and safety of guanfacine extended-release in Japanese adults with attention-deficit/hyperactivity disorder: Exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study. Naya N; Sakai C; Okutsu D; Kiguchi R; Fujiwara M; Tsuji T; Iwanami A Neuropsychopharmacol Rep; 2021 Mar; 41(1):26-39. PubMed ID: 33305542 [TBL] [Abstract][Full Text] [Related]
44. [An update on the pharmacological treatment of attention deficit hyperactivity disorder: lisdexamphetamine and extended-release guanfacine]. Martin Fernandez-Mayoralas D; Fernandez-Perrone AL; Munoz-Jareno N; Fernandez-Jaen A Rev Neurol; 2017 Mar; 64(s02):S1-S8. PubMed ID: 28272733 [TBL] [Abstract][Full Text] [Related]
45. An open-label, prospective study of guanfacine in children with ADHD and tic disorders. Boon-yasidhi V; Kim YS; Scahill L J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S156-62. PubMed ID: 16856436 [TBL] [Abstract][Full Text] [Related]
46. Effect on Primary Sleep Disorders When Children With ADHD Are Administered Guanfacine Extended Release. Rugino TA J Atten Disord; 2018 Jan; 22(1):14-24. PubMed ID: 25376194 [TBL] [Abstract][Full Text] [Related]
47. Guanfacine Extended Release for the Reduction of Aggression, Attention-Deficit/Hyperactivity Disorder Symptoms, and Self-Injurious Behavior in Prader-Willi Syndrome-A Retrospective Cohort Study. Singh D; Wakimoto Y; Filangieri C; Pinkhasov A; Angulo M J Child Adolesc Psychopharmacol; 2019 May; 29(4):313-317. PubMed ID: 30724590 [No Abstract] [Full Text] [Related]
48. Metabolite profiling of guanfacine in plasma and urine of healthy Japanese subjects after oral administration of guanfacine extended-release tablets. Inoue Y; Morita H; Nozawa K; Kanazu T Biopharm Drug Dispos; 2019 Sep; 40(8):282-293. PubMed ID: 31313320 [TBL] [Abstract][Full Text] [Related]
49. Guanfacine use in children with attention deficit hyperactivity disorder. Cohn LM; Caliendo GC Ann Pharmacother; 1997; 31(7-8):918-9. PubMed ID: 9220058 [TBL] [Abstract][Full Text] [Related]
50. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Sallee FR; Lyne A; Wigal T; McGough JJ J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):215-26. PubMed ID: 19519256 [TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended release. Roesch B; Corcoran M; Haffey M; Stevenson A; Wang P; Purkayastha J; Martin P; Ermer J Drugs R D; 2013 Mar; 13(1):53-61. PubMed ID: 23519656 [TBL] [Abstract][Full Text] [Related]
52. Combination treatment with guanfacine extended release and blonanserin for Tourette's syndrome comorbid with attention deficit hyperactivity disorder. Kawabe K; Horiuchi F; Ueno SI Psychiatry Clin Neurosci; 2019 Dec; 73(12):762-763. PubMed ID: 31588606 [No Abstract] [Full Text] [Related]
53. Guanfacine in children with autism and/or intellectual disabilities. Handen BL; Sahl R; Hardan AY J Dev Behav Pediatr; 2008 Aug; 29(4):303-8. PubMed ID: 18552703 [TBL] [Abstract][Full Text] [Related]
54. Drugs for ADHD. Med Lett Drugs Ther; 2020 Jan; 62(1590):9-15. PubMed ID: 31999670 [No Abstract] [Full Text] [Related]
55. Association between Early Guanfacine Discontinuation and Somnolence for Attention-Deficit/Hyperactivity Disorder. Doi K; Sogawa R; Eguchi Y; Matsuo M; Shimanoe C Biol Pharm Bull; 2024; 47(6):1204-1208. PubMed ID: 38910124 [TBL] [Abstract][Full Text] [Related]
56. Two case reports of extended-release guanfacine overdose in children. Shimozato A; Ohashi K; Saitoh S Pediatr Int; 2023 Jan; 65(1):e15424. PubMed ID: 36412228 [No Abstract] [Full Text] [Related]
57. Treatment Patterns, Health Care Resource Utilization, and Health Care Cost Associated with Atypical Antipsychotics or Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in Quebec, Canada. Lachaine J; Ben Amor L; Pringsheim T; Burns J; van Stralen J J Child Adolesc Psychopharmacol; 2019 Dec; 29(10):730-739. PubMed ID: 31433205 [No Abstract] [Full Text] [Related]
58. Guanfacine Use in Children With Down Syndrome and Comorbid Attention-Deficit Hyperactivity Disorder (ADHD) With Disruptive Behaviors. Capone GT; Brecher L; Bay M J Child Neurol; 2016 Jul; 31(8):957-64. PubMed ID: 26936058 [TBL] [Abstract][Full Text] [Related]
59. Guanfacine extended release in two patients with pervasive developmental disorders. Blankenship K; Erickson CA; Stigler KA; Posey DJ; McDougle CJ J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):287-90. PubMed ID: 21663433 [No Abstract] [Full Text] [Related]
60. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. Hunt RD; Arnsten AF; Asbell MD J Am Acad Child Adolesc Psychiatry; 1995 Jan; 34(1):50-4. PubMed ID: 7860456 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]